Center for Vascular Biology, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, Cornell University, New York, NY 10065, USA.
J Exp Med. 2012 Nov 19;209(12):2137-40. doi: 10.1084/jem.20122284.
Recent work has highlighted the multitude of biological functions of sphingosine 1-phosphate (S1P), which include roles in hematopoietic cell trafficking, organization of immune organs, vascular development, and neuroinflammation. Indeed, a functional antagonist of S1P(1) receptor, FTY720/Gilenya, has entered the clinic as a novel therapeutic for multiple sclerosis. In this issue of the JEM, Zhang et al. highlight yet another function of this lipid mediator: thrombopoiesis. The S1P(1) receptor is required for the growth of proplatelet strings in the bloodstream and the shedding of platelets into the circulation. Notably, the sharp gradient of S1P between blood and the interstitial fluids seems to be essential to ensure the production of platelets, and S1P appears to cooperate with the CXCL12-CXCR4 axis. Pharmacologic modulation of the S1P(1) receptor altered circulating platelet numbers acutely, suggesting a potential therapeutic strategy for controlling thrombocytopenic states. However, the S1P(4) receptor may also regulate thrombopoiesis during stress-induced accelerated platelet production. This work reveals a novel physiological action of the S1P/S1P(1) duet that could potentially be harnessed for clinical translation.
最近的研究强调了鞘氨醇 1-磷酸(S1P)的多种生物学功能,包括在造血细胞迁移、免疫器官组织、血管发育和神经炎症中的作用。事实上,S1P(1)受体的功能性拮抗剂 FTY720/Gilenya 已作为多发性硬化症的新型治疗药物进入临床。在本期《JEM》中,Zhang 等人强调了这种脂质介质的另一个功能:血小板生成。S1P(1)受体是在血液中形成原血小板串并将血小板释放到循环中的必需条件。值得注意的是,S1P 在血液和间质液之间的陡峭梯度似乎对确保血小板的产生至关重要,并且 S1P 似乎与 CXCL12-CXCR4 轴合作。S1P(1)受体的药理学调节可急性改变循环血小板数量,提示控制血小板减少症状态的潜在治疗策略。然而,S1P(4)受体也可能在应激诱导的加速血小板生成期间调节血小板生成。这项工作揭示了 S1P/S1P(1)二重奏的一种新的生理作用,可能有潜力用于临床转化。